<DOC>
	<DOCNO>NCT02346669</DOCNO>
	<brief_summary>The incidence obesity dramatically increase last three decade , lead significant increase obesity-related morbidity , include type 2 diabetes mellitus ( T2DM ) characterize resistance target tissue insulin action . T2DM obese patient may treat medication bariatric surgery . Both alternative limitation due incomplete resolution disease , high cost potential procedural relate morbidity . An increase body evidence point role enteric microbiota pathogenesis obesity-related insulin resistance . In addition , gut microbiota directly affect diet composition . Studies T2DM mouse carry human gut germ , demonstrate special interaction gut microbiota host , create typical microbiota composition change significantly follow diet change western diet , rich sugar , vegetarian diet rich fiber . This rapid alternation microbiota composition also show human , change western high fiber diet . A change diet life style may lead improvement T2DM symptom decrease visceral adipose tissue .</brief_summary>
	<brief_title>Fecal Microbiota Transplantation Diabetes Mellitus Type II Obese Patients</brief_title>
	<detailed_description>Study design : 30 Patients undergo 2 FMT 's lean donor randomize 3 type diet group : 1. low fat high fiber diet ( 20 % fat ) 2. change fat intake ( sham diet ) 3. high fat low fiber diet ( 40-45 % fat ) The treat physician patient blind diet arm . Before FMT , patient assess overnight fast ( take medication ) weight , anthropometric measure , questionnaire ( dietary , general health , antibiotic probiotic exposure , oral diabetes medication quantity , drug exposure ) , blood stool . The investigator hypothesize fecal microbial transplantation lean donor T2DM obese patient , combination low fat high fiber diet , alter gut microbiota composition decrease insulin resistance microbiota dependent metabolic immunologic effect .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>30≤BMI A diagnosis T2DM ( ≥3 month ) one following : 1 . Fasting glucose level≥126mg/dL and/ 2 . A stable dose antidiabetic drug ≥2 week and/or 3 . HbA1C≥6.5 Access smart phone support research application track food consumption . participation clinical trial incapable signing informed consent pregnancy breast feed Antibiotic treatment within prior 3 month predict antibiotic treatment insulin medication drug alcohol addiction immune mediate disease type 1 diabetes latent autoimmune diabetes adult systemic disease ischemic heart disease probiotic consumption new unstable treatment anti diabetic medication Patients also exclude : treat systemic antibiotic study compliant diet</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Microbiota</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Obesity</keyword>
</DOC>